Logo

Takeda Receives the US FDA Advisory Committee's Recommendation for TAK-620 (maribavir) to Treat CMV Infection in Post-Transplant Recipients

Share this

Takeda Receives the US FDA Advisory Committee's Recommendation for TAK-620 (maribavir) to Treat CMV Infection in Post-Transplant Recipients

Shots:

  • The US FDA’s AMDAC voted to recommend the use of maribavir (TAK-620) to treat refractory CMV infection and disease with/out genotypic resistance to ganciclovir- valganciclovir- foscarnet- or cidofovir in transplant recipients
  • The recommendations were based on the results from the P-II & III TAK-620-303 (SOLSTICE) trials of maribavir while the NDA submission of maribavir is based on the P-III TAK-620-303 (SOLSTICE) trial & is currently under the US FDA’s priority review
  • Maribavir has received EC’s OD designation for CMV in patients with impaired cell-mediated immunity and US FDA’s ODD for CMV viremia & at-risk patients

Ref: Takeda | Image: Takeda

Click here to­ read the full press release 

Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions